Test Directory

MRD monitoring BCR::ABL1 E13A2 and/or E14A2 transcripts

Containers - Adult

RedCapTubeEDTAKE9ml.jpg
Red Cap Tube EDTA KE 9ml
Volume Range

2 x 9ml Peripheral blood or bone marrow specimen​
Additive per Container

EDTA

Laboratory Site

WGH
Crewe Road South
Edinburgh
EH4 2XU
Telephone: 0131 537 1000

Transport arrangements

Blood and bone marrow specimens should ideally arrive within 24 hours of collection (maximum of 48 hours).  Specimens should arrive no later than 3.30pm on Friday.  Samples should be sent to the following address:

Western General Hospital

Haematology/Biochemistry Combined Reception

Immunophenotyping Laboratory

Crewe Road

Edinburgh

EH4 2XU​

 

See also Specimen transportation.

Sample storage arrangements

Samples should be stored at room temperature. See specimen requirements.​

How to request

Requests may be made using our request form or via TRAK.  Please refer to our detailed requesting ​instructions.  The HMDS request form can be located here.​

HMDS request form PDF_v5.pdf

Availability

Monday-Friday 9am-5pm

Anticipated turnaround

Results should be expected within 10 working days.  See results.

What happens if the result is positive or abnormal

The requesting clinician will be contacted where results are clinically significant. Please ensure details are included on request form. 

Static information/disclaimer

This test is accredited to ISO 15189:2012

General additional information

This test is MRD monitoring for patients with BCR::ABL1 E13A2/E14A2 transcript only (often termed P210).   For patients with other BCR::ABL1 fusion transcript types this test is not appropriate.  For patients with BCR::ABL1 E1A2 transcript please see MRD monitoring for BCR::ABL1 E1A2.

For suspected CML samples, refer to BCR::ABL1 diagnostic test and for AML and ALL diagnostic samples refer to AML and ALL panel testing respectively. 

This assay is performed to quantify E13A2 and/or E14A2 BCR::ABL1 transcripts in patients known to carry this specific fusion transcript.

Monitoring of the level of BCR::ABL1 fusion transcript is vital for the assessment of response to tyrosine kinase inhibitor therapy and the early identification of therapy resistance. BCR::ABL1 RT-qPCR monitoring is indirectly calibrated against primary WHO reference standards and is reported on the International Scale.

For patients demonstrating a significant rise in BCR::ABL1/ABL1 ratio, an assessment for BCR::ABL1 tyrosine kinase domain testing is available.

For clinical advice on appropriate investigations and advice for the interpretation of test results, please see contact us​.